GCP
TPST icon

GSA Capital Partners’s Tempest Therapeutics TPST Stock Holding History

GSA Capital Partners’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,301
Closed -$133K – 2035
2024
Q3 		$133K Sell
7,301
-472
-6% -$9.67K 0.01% 1462
2024
Q2 		$221K Buy
+7,773
New +$336K 0.02% 1426
2017
Q3 		– Sell
-3
Closed -$16K – 1887
2017
Q2 		$16K Buy
+3
New +$12.7K ﹤0.01% 1636
2015
Q3 		– Sell
-15
Closed -$1.24M – 2015
2015
Q2 		$1.24M Buy
15
+4
+36% +$366K 0.05% 718
2015
Q1 		$1.14M Buy
+11
New +$1.46M 0.05% 760

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

GSA Capital Partners's TPST Position: Q4 2024 in Review

GSA Capital Partners sold out of Tempest Therapeutics (TPST) in Q4 2024, closing a stake of 7,301 shares — an estimated $133K sold.

GSA Capital Partners first reported a position in TPST in Q1 2015 and held it in 5 quarters. The position peaked at $1.24M in Q2 2015. 33 funds tracked by Wall St. Rank hold TPST as of Q4 2024.

  • GSA Capital Partners reported no remaining Tempest Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 7,301 Tempest Therapeutics shares in Q4 2024, an estimated $133K.
  • GSA Capital Partners first reported a position in Tempest Therapeutics in Q1 2015 and held it in 5 quarters.
  • GSA Capital Partners's Tempest Therapeutics position peaked at $1.24M in Q2 2015.
  • 33 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.